Literature DB >> 16634913

Successful treatment of systemic sclerosis-related digital ulcers and sarcoidosis with endothelin receptor antagonist (bosentan) therapy.

J Tillon, F Hervé, D Chevallier, J-F Muir, H Levesque, I Marie.   

Abstract

Entities:  

Mesh：

Substances：

Year:  2006        PMID： 16634913     DOI： 10.1111/j.1365-2133.2006.07194.x

Source DB:  PubMed          Journal:  Br J Dermatol        ISSN： 0007-0963            Impact factor:   9.302


× No keyword cloud information.
  5 in total

Review 1.  Functional autoantibodies in systemic sclerosis.

Authors:  Jeannine Günther; Judith Rademacher; Jakob M van Laar; Elise Siegert; Gabriela Riemekasten
Journal:  Semin Immunopathol       Date:  2015-08-21       Impact factor: 9.623

2.  [Treatment of a leg ulcer with bosentan in a female patient with progressive systemic scleroderma].

Authors:  I Rösener; A Rübben
Journal:  Hautarzt       Date:  2007-05       Impact factor: 0.751

Review 3.  Recent advances in the treatment of systemic sclerosis.

Authors:  Vasiliki Kalliopi K Bournia; Panayiotis G Vlachoyiannopoulos; Carlo Selmi; Haralampos M Moutsopoulos; M Eric Gershwin
Journal:  Clin Rev Allergy Immunol       Date:  2009-06       Impact factor: 8.667

4.  Effects of bosentan on the skin lesions: an observational study from a single center in Japan.

Authors:  Masanori Funauchi; K Kishimoto; H Shimazu; Y Nagare; S Hino; T Yano; K Kinoshita
Journal:  Rheumatol Int       Date:  2008-11-27       Impact factor: 2.631

5.  Endothelin Receptor Antagonists for the Treatment of Raynaud's Phenomenon and Digital Ulcers in Systemic Sclerosis.

Authors:  Kait Arefiev; David F Fiorentino; Lorinda Chung
Journal:  Int J Rheumatol       Date:  2011-10-27
  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.